08:06 EST Krystal Biotech sees 2024 non-GAAP R&D, SG&A expense $150M-$175M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
- Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Krystal Biotech receives FDA Fast Track Designation for KB707
- Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
- Krystal Biotech announces publication in NEJM on application of B-VEC